Ionis Pharmaceuticals IONS Total debt

Total debt at other companies

Eli LillyLLY

$54.91B+37.6%

PfizerPFE

$64.43B+4.9%

Arrowhead ResearchARWR

$107.88M-5.6%

BioCryst PharmaceuticalsBCRX

$410.95M+59.9%

ALN

Alnylam PharmaceuticalsALNY

$256.43M-5.2%

Stoke Therapeutics, Inc.STOK

$3.42M-42.5%

FAQ

What is Ionis Pharmaceuticals's total debt?

Ionis Pharmaceuticals (IONS) reported total debt of $262.48M in Q2 2026.

How has Ionis Pharmaceuticals's total debt changed year-over-year?

Ionis Pharmaceuticals's total debt decreased by 67.0% year-over-year, from $794.5M to $262.48M.

What is the long-term trend for Ionis Pharmaceuticals's total debt?

Over 5 years (2020 to 2025), Ionis Pharmaceuticals's total debt has grown at a 46.1% compound annual growth rate (CAGR), from $370.46M to $2.46B.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.